Pfizer Is Moving Beyond Covid. Why Its Stock Is a Buy.

Pfizer probably did more than any other company to help the world normalize from the pandemic, and it reaped a financial windfall from its twin Covid-19 franchise—the top-selling vaccine and the leadi...

Eli Lilly and Novo Stock Sold Off. Don’t Blame Their Diet Drugs.

Stock in Eli Lilly and Novo Nordisk outperformed last year, largely because of remarkable demand for new drugs that drive weight loss in patients afflicted with diabetes and obesity. Both stocks were ...

Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.

Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon. With real...

California Sues Eli Lilly And Other Insulin Makers For Driving Up Drug Cost

Topline California is suing a group of pharmacy benefit managers and insulin manufacturers, including pharmaceutical giant Eli Lilly, for using “unlawful, unfair and deceptive” means to drive up the c...

It’s Pharma Time: Why Merck and Lilly Stock Are Buys, but not Pfizer.

My 2023 biotech outlook calls for continued momentum in name changes. I just need to figure out what the stocks will do. Last year, Respira Technologies became Qnovia. It’s run by a former tobacco exe...

Why Pfizer Is Pulling Back on Research Into Rare Disease, Gene Therapy

Pfizer is planning to pull back on early-stage research into treatments for rare diseases, including the development of new viral-based gene therapies, the company told employees on Thursday afternoon...

Nucor, CVS, and 11 More Companies That Raised Their Stock Dividends This Week

Eli Lilly Amgen Nucor and Franklin Resources were among the many companies that declared dividend increases this week. Eli Lilly (ticker: LLY) declared a quarterly payout of $1.13 a share, an increase...

Musk Issues New Rule For Parody Twitter Accounts After ‘Verified’ Impersonators Cause Chaos

Topline Twitter CEO Elon Musk on Thursday night outlined the latest set of rules under which parody accounts will operate, including clear identification, hours after multiple impersonator accounts wh...

Eli Lilly Clarifies It’s Not Offering Free Insulin After Tweet From Fake Verified Account—As Chaos Unfolds On Twitter

Topline Pharmaceutical company Eli Lilly clarified Thursday it is not offering free insulin, after a fake Twitter account—which was verified through Twitter Blue, a new subscription service implemente...

Pfizer’s Earnings Are Tuesday. What to Watch.

Pfizer is set to report its earnings on Tuesday, a week and a half after an executive told investors that the company was considering a list price for its Covid-19 vaccine of between $110 and $130 per...

Buy Merck And Eli Lilly

Photographer: Michael Nagle/Bloomberg © 2022 Bloomberg Finance LP The coming week is post options expiration week in October. The histogram below tells us that this week has a bearish tinge. S&P 5...

An Alzheimer’s Drug’s Big Surprise: What It Means

Until this past week, there seemed to be no answers to the Alzheimer’s puzzle. The leading theory of the disease, that it was caused by a buildup of beta amyloid plaque in the brain, had been disprove...

Buy Eli Lilly Stock. Its Obesity Drug Mounjaro Will Be a Hit, Analyst Says.

Text size Eli Lily said in August that initial demand for Mounjaro was strong. Daniel Acker/Bloomberg Eli Lilly’s novel treatment for diabetes and obesity could become one of history’s bestselling dru...

Where Is the Stock Market Going? It Could Have a Messy Fall.

If 2022 were to end tomorrow, or the day after, it would enter the books as a dismal one for investors. The Dow Jones Industrial Average is down 13% year to date, the S&P 500 index is off 17%, and...

Ups & Downs: Top Pharmaceutical Stocks Post-COVID

Who will be Big Pharma’s winners post-COVID? Getty Images There’s little argument that the COVID-19 pandemic reshaped the world. While families and governments continue to grapple with Omicron v...

Uber, Boeing, Warner Bros. Discovery: Stocks That Defined the Week

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple ...

Novartis Will Cut 8,000 Jobs Under CEO’s Shake-Up Plan

Text size Vasant Narasimhan, CEO of Novartis. ERIC PIERMONT/AFP/Getty Images Pharmaceutical giant Novartis said Tuesday it will lay off more than 7% of its workforce, just a few months after CEO Vas N...

The Days of Big Pharma Are Over. Big Biotech Is on Its Way.

W hen GlaxoSmithKline spins off its enormous division selling drugstore staples like Advil and Tums next month, it will represent more than just the latest shuffling of assets among corporate giants. ...

Stocks Are Ready for a Bounce Higher After S&P 500 Closes Above Bear Market

Text size Dreamstime The stock market came awfully close to finishing Friday in a bear market, at least 20% off its peak in early January. Many investors would like to see it get there so Wall Street ...

Pfizer’s New CFO David Denton Negotiated One of the Biggest Healthcare Deals in History

Pfizer on Monday named a new chief financial officer with a resume that hints at the company’s plans to spend big with its Covid-19 vaccine windfall. David Denton is taking up the CFO role at Pfizer (...

FDA Authorizes Eli Lilly Antibody Treatment That Fights Omicron

Topline The Food and Drug Administration on Friday issued an emergency use authorization for a new monoclonal antibody treatment that drugmaker Eli Lilly says works against the coronavirus’ omicron va...

U.S. Stock Futures Poised for Lower Open on Monday

Stocks are poised to open lower on Monday. Michael Nagle/Bloomberg Text size Here’s what you need to know to navigate the markets today. • U.S. stocks are set to open Monday slightly down. On Sunday n...

Biogen’s Alzheimer’s Drug Aduhelm Has Another Shot at Success

Illustration by Elias Stein Text size Biogen ’s Alzheimer’s disease therapy, Aduhelm, has been a disappointment for the company since its Food and Drug Administration approval last spring, with early ...